Omega Funds and TCG X led a $153m Series C round in Artios Pharma.

Omega Funds and TCG X led a $153m Series C round in Artios Pharma, a DNA Damage Response company, with participation from Avidity Partners, Invus, Deep Track Capital, Sofinnova Partners, Tetragon Financial Group, RTW Investments, Soleus Capital, Piper Heartland Healthcare Capital, CaaS Capital Management, and Schroders Capital. "Artios’ deep expertise in DNA damage response and novel approach to drive the search for new and better cancer treatments is an ideal match for Omega Funds. Supporting Artios in its mission to advance its portfolio of best-in-class and first-in-class small molecule DDR programs, including its DNA polymerase theta (Polθ) inhibitor, which is poised to enter the clinic, is a welcome addition to our portfolio of life science investments targeting our world's most urgent medical needs," Michelle Doig, Omega Funds Partner, Head of Corporate Development.